Synlogic Inc. and Caldera Therapeutics Inc. have announced a definitive all-stock merger to create a new public entity focused on inflammatory diseases. The combined company, operating as Caldera Therapeutics, is supported by a concurrent $278 million private placement. This transaction aims to accelerate development of Caldera's lead drug candidate for inflammatory bowel disease.
Merger Structure and Financial Details
The transaction will form a new holding company named Caldera Therapeutics, which will apply for a Nasdaq listing under the ticker CALD. Both Synlogic and Caldera will become wholly-owned subsidiaries of this new public entity. The merger is structured as an all-stock deal combining the assets of both organizations.
Upon closing, pre-merger Caldera stockholders will hold approximately 62.8% of the new company, with private placement investors owning 34.9%. Synlogic's stockholders will retain an approximate 2.3% stake, subject to adjustments based on net cash. This structure reflects the relative valuations and new capital infusion.
A syndicate of prominent healthcare investors, including Bain Capital Life Sciences, has committed to the $278 million private placement. This financing, combined with existing cash, is projected to fund operations into 2029. The capital provides a robust foundation for advancing the company's clinical programs.
Advancing a Novel IBD Treatment
The new company's primary focus will be CLD-423, an investigational bispecific antibody for treating inflammatory bowel disease. This novel therapeutic is designed to simultaneously inhibit the TL1A and IL-23p19 pathways. Caldera holds exclusive worldwide rights to the drug under a license agreement.
CLD-423 has completed dosing in a Phase 1 clinical trial with healthy volunteers in Australia. Early data indicated the drug was generally well tolerated with no dose-limiting toxicities observed. The results also showed a promising serum half-life and strong subcutaneous bioavailability.
With the new funding secured, Caldera plans to advance CLD-423 into Phase 2 clinical development. The initial focus for these mid-stage trials will be on treating patients with ulcerative colitis and Crohn's disease. This next phase is critical for evaluating the drug's efficacy in target patient populations.
Leadership and Transaction Timeline
Praveen Tipirneni, the current Chief Executive Officer of Caldera Therapeutics, is set to lead the combined company. His leadership will provide continuity for the development strategy of the company's lead asset. The new management team will guide the integrated organization following the merger's completion.
The merger has received unanimous approval from the boards of directors of both Synlogic and Caldera. The transaction remains subject to several customary closing conditions. These include obtaining approval from stockholders of both companies and SEC registration effectiveness.
The deal is anticipated to close by early 2027, pending the fulfillment of all necessary conditions. Stockholders representing a majority of shares in both companies have already signed support agreements. This backing signals confidence in the strategic rationale behind the combination.
This merger is a significant strategic move, launching Caldera as a publicly traded and well-capitalized biopharmaceutical company. The substantial financing ensures a long operational runway to pursue a promising new treatment for inflammatory bowel disease. The transaction provides a new path for Synlogic's stakeholders while positioning the combined entity for growth.